RxDoctor Payments Data

Alla Nirenberg, MD

Psychiatry · Elmsford, NYNPI 1336223544

Payments from drug & device makers

$134,341in general payments, 2019–2025

Across 420 payments — averaging $319.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$46K
  • Axsome Therapeutics, Inc.$46K
  • Otsuka America Pharmaceutical, Inc.$38K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$958
  • Lundbeck LLC$544
  • plus $2K from 8 others

What the payments were for

  • Consulting fees$30,30023%
  • Speaking & faculty fees$86,59864%
  • Travel & lodging$5,1404%
  • Food & beverage$12,1909%
  • Education$1130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,341 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$17,300
Medicare patients
33
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl133$182,093
IngrezzaValbenazine Tosylate13$101,716
RexultiBrexpiprazole43$90,187
NuedextaDextromethorphan Hbr/Quinidine11$9,194
Lurasidone Hcl23$4,940
Bupropion XlBupropion Hcl131$3,982
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$3,921
Divalproex Sodium84$3,914
Aripiprazole135$3,536
Divalproex Sodium ErDivalproex Sodium66$3,513
Oxcarbazepine22$2,553
Duloxetine Hcl79$2,490
Ziprasidone Hcl37$2,384
Quetiapine Fumarate113$2,336
Quetiapine Fumarate ErQuetiapine Fumarate47$2,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$46,426$182,093133 claims
Neurocrine Biosciences, Inc.Ingrezza$523$101,71613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$37,642$90,18743 claims
Almatica Pharma LLCSertraline Hcl$138$1,032131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Elmsford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →